CRISM Therapeutics Corporation (AIM:CRTX)
London · Delayed Price · Currency is GBP · Price in GBX 9.53
-0.22 (-2.26%)
Sep 25, 2026, 1:49 PM GMT
CRISM Therapeutics Income Statement
Financials in millions GBP. Fiscal year is January - December.
Millions GBP. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | - | - | - | 0.05 | - | - |
Other Revenue | 0.35 | 0.23 | 0.03 | - | - | - |
| 0.35 | 0.23 | 0.03 | 0.05 | - | - | |
Revenue Growth | 1308.00% | 824.00% | -44.44% | - | - | - |
Cost of Revenue | 0.13 | 0.1 | 0 | 0.03 | - | - |
Gross Profit | 0.23 | 0.13 | 0.02 | 0.01 | - | - |
Selling, General & Admin | 1.67 | 1.05 | 0.7 | 0.14 | 1.85 | 1.32 |
Research & Development | 0.91 | 0.91 | 0.17 | 0.03 | - | - |
Other Operating Expenses | 0.03 | 0.03 | 0.02 | - | - | - |
Operating Expenses | 2.62 | 2.01 | 0.9 | 0.18 | 1.85 | 1.32 |
Operating Income | -2.4 | -1.88 | -0.88 | -0.17 | -1.85 | -1.32 |
Interest Expense | - | - | -0.01 | -0.03 | - | - |
Currency Exchange Gain (Loss) | - | - | - | - | - | -0 |
EBT Excluding Unusual Items | -2.4 | -1.88 | -0.89 | -0.2 | -1.85 | -1.32 |
Other Unusual Items | - | - | 0.3 | - | -0.32 | - |
Pretax Income | -2.4 | -1.88 | -0.59 | -0.2 | -2.16 | -1.32 |
Income Tax Expense | -0.01 | -0 | - | -0.01 | - | - |
Earnings From Continuing Operations | -2.39 | -1.88 | -0.59 | -0.2 | -2.16 | -1.32 |
Earnings From Discontinued Operations | - | -0.03 | -0.01 | - | -0.34 | 0.43 |
Net Income | -2.39 | -1.9 | -0.61 | -0.2 | -2.5 | -0.89 |
Net Income to Common | -2.39 | -1.9 | -0.61 | -0.2 | -2.5 | -0.89 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 48 | 36 | 32 | 0 | 9 | 9 |
Shares Outstanding (Diluted) | 48 | 36 | 32 | 0 | 9 | 9 |
Shares Change | 4.77% | 13.32% | 201033.86% | -99.82% | 0.85% | 28.82% |
EPS (Basic) | -0.05 | -0.05 | -0.02 | -12.25 | -0.29 | -0.10 |
EPS (Diluted) | -0.05 | -0.05 | -0.02 | -12.25 | -0.29 | -0.10 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -2.58 | -1.97 | -0.93 | -0.1 | -2.92 | -1.67 |
Free Cash Flow Per Share | -0.05 | -0.05 | -0.03 | -6.13 | -0.34 | -0.19 |
Gross Margin | 64.20% | 56.71% | 84.00% | 28.89% | - | - |
Operating Margin | -681.25% | -812.99% | -3520.00% | -377.78% | - | - |
Profit Margin | -677.84% | -823.81% | -2428.00% | -435.56% | - | - |
Free Cash Flow Margin | -732.67% | -851.51% | -3732.00% | -217.78% | - | - |
EBITDA | -2.38 | -1.86 | -0.86 | -0.15 | -1.62 | -1.12 |
D&A For EBITDA | 0.02 | 0.02 | 0.02 | 0.02 | 0.23 | 0.2 |
EBIT | -2.4 | -1.88 | -0.88 | -0.17 | -1.85 | -1.32 |